Details for Patent: 10,052,267

Which drugs does patent 10,052,267 protect, and when does it expire?

Patent 10,052,267 protects QBREXZA and is included in one NDA.

This patent has eight patent family members in six countries.

Summary for Patent: 10,052,267

Title:	Topical glycopyrrolate formulations
Abstract:	Individually packaged topical formulations comprising about 0.25 to about 6% w/w of glycopyrrolate for the treatment of hyperhidrosis, wherein said wipe is contained within a pouch resistant to leakage. The formulations may further comprise ethanol, a buffering agent and water. In addition, the formulations may further comprise a polymer system comprising a hydrophobic polymer in combination with a hydrophilic polymer.
Inventor(s):	Johnston; Michael (Yarraville, AU), Houlden; Robert James (Kilsyth, AU)
Assignee:	ROSE U, LLC (Palo Alto, CA)
Application Number:	15/662,166
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,052,267
Patent Claim Types: see list of patent claims	Use; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 10,052,267

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Journey	QBREXZA	glycopyrronium tosylate	CLOTH;TOPICAL	210361-001	Jun 28, 2018		RX	Yes	Yes			Y			TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER

International Family Members for US Patent 10,052,267

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2008314628
Australia	2014203072
Canada	2702830
European Patent Office	2200550
European Patent Office	3415127